MarketVIEW: *Acinetobacter baumannii* vaccines (CAT: VAMV070)

Product Name	:	**MarketVIEW:** *Acinetobacter baumannii* vaccines
Description	:	*Acinetobacter baumannii* vaccines: global market forecast and size
Contents	:	Executive presentation (~97 slides .pdf) + 1 MS Excel workbook (.xls)
Therapeutic Area	:	New/hospital vaccines
Publication date	:	May 2019
Catalogue No	:	VAMV070

Background

Acinetobacter baumannii **(AB)** of the *Acinetobacter* spp is a ubiquitous aerobic Gram-negative bacillus which preferentially colonises aquatic environments. Because of its high propensity for antimicrobial resistance, the bacterium has become a **WHO "Priority No 1" pathogen** and poses a critical threat to global human health. AB is associated with around ~1-2% of hospital-acquired infections (HAIs) where colonization is associated with an increased risk of hospital death. Patients usually affected are the critically ill and/or immune-compromised, having been admitted to the intensive care unit (ICU) and often receiving mechanical ventilation. In these instances, AB pneumonia can have high mortality rates (>50%) and importantly, infections can be challenging to treat with current antibiotics especially multidrug-resistant forms **MDR**, **XDR** and **PDR**. AB resistant infections dramatically increase hospital length of stay (LOS) and economic cost.

There are many drivers to justify the search for **new management techniques** to *A.baumannii* infections especially immunologic approaches such as prophylatic vaccines and monoclonal antibodies. Several companies have an ongoing preclinical interest such as **ALOPEXX**, **Vaxdyn** and **Aridis Pharmaceuticals** and larger manufacturers would be well advised to be involved. *Acinetobacter baumannii* is a unique concern, and it is not prudent to evaluate AB alongside high-volume comparators that also have an antimicrobial resistance threat.

This **MarketVIEW** product is composed of a comprehensive Executive summary presentation (~100 slides, .pdf) + MS Excel-based model which forecasts the potential commercial value of a putative *Acinetobacter baumannii* vaccine across major Western markets to 2030[1]. Three deployment scenarios (LO, BASE and HI) are included based upon successive targeting of patient groups (and specific subsets) who would benefit from vaccination. A detailed review of disease background and epidemiology is included along with current treatment, unmet needs and rationale for vaccine approach. An ideal **Target Product Profile** (TPP) is defined along with commercial model assumptions with economic pricing justification. This analysis is ideally suited to any organisation wishing to understand and justify investment into this highly important opportunity.

---

[1] United States, Canada, Major 5 EU, Other EU and Australia

Bringing life to vaccine strategy...   www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 813155 e-mail: info@vaczine-analytics.com

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to *Acinetobacter baumannii* epidemiology, hospital in-patient datasets, vaccine development, competitive environment, recommendations, policy. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings, news articles, expert comment etc.

PRODUCT CONTENTS:
Published May 2019 (CAT No: VAMV070)

****This product is a summary presentation (.pdf), a forecast model (.xls)

Contents – Summary presentation (.pdf)[2]

Contents
Author's notes
Executive summary
[SECTION 1] *Acinetobacter baumannii* vaccines: key commercial model outputs
[SECTION 2] *Acinetobacter baumannii*: disease background
[SECTION 3] *Acinetobacter baumannii*: disease epidemiology (global)
[SECTION 4] *Acinetobacter baumannii*: current treatment and management
[SECTION 5] *Acinetobacter baumannii*: R&D summary and rationale for vaccine development
[SECTION 6] *Acinetobacter baumannii*: modelling vaccine commercial potential
Bibliography
Disclaimer

PAGES: ~100 slides fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Worksheets = >50 interconnected

---

[2] Full contents i.e. title per slide is proprietary and only available upon valid request

Bringing life to vaccine strategy...

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 813155 e-mail: info@vaczine-analytics.com

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- o   FULL PRODUCT (All deliverables) - USD **$8,995**/ GBP **£6,900**# (Region license)*

Indicative company rate only. Prevailing rate applied to the date of transaction.
*A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to the final invoice total
Agency/consultancy rates (commercial use) are available upon request

HOW TO ORDER:

To order, please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased online. Please review the **TERMS and CONDITIONS** of purchase.

Bringing life to vaccine strategy...   www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44(0)1279 813155 **e-mail: info@vaczine-analytics.com**

BIBLIOGRAPHY

.

~96 references are included in this study

Bringing life to vaccine strategy...

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44(0)1279 813155 **e-mail: info@vaczine-analytics.com**

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as "The Company"). (Herein [enter client name] to as "The Client").

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (a division of Assay Advantage Ltd).

2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.

3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.

4. If not purchased online invoices are payable within **thirty days** of the invoice date.

5. All proposals are quoted in **$USD dollars, or £GBP or €euro** and invoices are to be settled in the same currency.

6. The Company agrees not to disclose to any third-party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees, and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.

7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.

8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics
of division of Assay Advantage Ltd
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 813155
E-mail: info@vacZine-analytics.com

Bringing life to vaccine strategy...   www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom   Tel. +44(0)1279 813155   e-mail: info@vaczine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009